Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) Director Adam K. Stern bought 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The shares were bought at an average price of $0.82 per share, with a total value of $12,300.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
NYSEAMERICAN MTNB traded down $0.03 on Friday, hitting $0.80. The company’s stock had a trading volume of 7,953 shares, compared to its average volume of 1,043,651. Matinas BioPharma Holdings Inc has a 52-week low of $0.32 and a 52-week high of $1.50.
Matinas BioPharma (NYSEAMERICAN:MTNB) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.01).
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC raised its position in shares of Matinas BioPharma by 190.1% in the 1st quarter. Jane Street Group LLC now owns 41,452 shares of the company’s stock worth $45,000 after acquiring an additional 27,165 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in shares of Matinas BioPharma in the 1st quarter worth approximately $107,000. ExodusPoint Capital Management LP bought a new position in shares of Matinas BioPharma in the 1st quarter worth approximately $42,000. Broadfin Capital LLC bought a new position in shares of Matinas BioPharma in the 1st quarter worth approximately $2,973,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Matinas BioPharma in the 1st quarter worth approximately $39,000.
Several equities research analysts recently weighed in on MTNB shares. Zacks Investment Research upgraded Matinas BioPharma from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a report on Tuesday, April 16th. Maxim Group reiterated a “buy” rating and issued a $5.00 price objective on shares of Matinas BioPharma in a report on Thursday, May 16th. Finally, BTIG Research started coverage on Matinas BioPharma in a report on Friday, May 17th. They issued a “buy” rating and a $5.00 price objective for the company.
About Matinas BioPharma
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Further Reading: What is the Consumer Price Index (CPI)?
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.